NCT03215277: A reported trial by UCB Biopharma SRL
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03215277 |
|---|---|
| Title | A Multicenter, Phase 2A, Randomized, Investigator-Blind, Subject-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Subjects With Active Ankylosing Spondylitis |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 4, 2017 |
| Completion date | May 25, 2020 |
| Required reporting date | May 25, 2023, midnight |
| Actual reporting date | May 19, 2023 |
| Date last checked at ClinicalTrials.gov | April 20, 2026 |
| Days late | None |